一名13岁脓疱型银屑病患者英夫利昔单抗超敏反应的新型脱敏方案
A Novel Desensitization Protocol for Infliximab Hypersensitivity in a 13-Year Old Patient with Pustular Psoriasis.
作者信息
Behera Sapan Kumar, Selvarajan Sandhiya, Mathews Jerene, Shajil Chandana, Das Saibal, Munisamy Malathi, Xavier Alphienes Stanley
机构信息
Department of Clinical Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, (JIPMER), Puducherry, India.
Department of Dermatology & STD, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.
出版信息
Curr Drug Saf. 2019;14(2):158-162. doi: 10.2174/1574886314666190119115632.
BACKGROUND
Drug hypersensitivity reactions to infliximab have been reported in pediatric patients. At times, these patients may need infliximab administration in spite of hypersensitivity. However, only a few reports of desensitization protocols are available in the literature in pediatric patients.
CASE REPORT
We report a case of immediate hypersensitivity reaction to intravenous infliximab in a 13-year-old child suffering from pustular psoriasis who eventually underwent a 14 step desensitization protocol for the administration of infliximab in a pediatric intensive care unit.
RESULTS AND CONCLUSION
Although our desensitization protocol was safe and effective, we recommend the entire desensitization procedure to be performed under the supervision of experienced personnel in a pediatric intensive care unit. Future studies with larger sample size are needed to confirm our findings.
背景
儿科患者中已报道有对英夫利昔单抗的药物过敏反应。有时，尽管存在过敏反应，这些患者可能仍需要使用英夫利昔单抗。然而，文献中关于儿科患者脱敏方案的报道很少。
病例报告
我们报告一例13岁脓疱型银屑病患儿对静脉注射英夫利昔单抗发生即刻过敏反应的病例，该患儿最终在儿科重症监护病房接受了14步英夫利昔单抗脱敏方案。
结果与结论
尽管我们的脱敏方案安全有效，但我们建议整个脱敏过程在儿科重症监护病房有经验的人员监督下进行。需要进行更大样本量的未来研究来证实我们的发现。
Zotero 插件